Modulation of the renin-angiotensin system is considered to be the most complete way to manage high-risk patients including those with hypertension. Angiotensin-converting enzyme (ACE) inhibitors are effective at reducing the morbidity and mortality of patients with overt clinical heart failure, asymptomatic left ventricular dysfunction, and uncomplicated myocardial infarction. Furthermore, recent trials like the Heart Outcomes Prevention Evaluations (HOPE) study and the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) support extending the use of ACE inhibitors to the routine/first-line treatment of patients with an increased global cardiovascular risk. Although some investigators have seen the development of angiotensin II receptor blockers (ARBs) as a more effective and tolerable way of reproducing the benefits of ACE inhibition, there remain important concerns regarding the distinct pharmacologic profiles and modes of action of these two classes of drugs. Careful evaluation of data from recent largescale studies revealed that, unlike ACE inhibitors, ARBs are either neutral or may actually increase rates of myocardial infarction despite similar levels of blood pressure reduction. The fact that this effect is most apparent when ARBs are compared with placebo in the absence of concomitant ACE inhibitors suggests that differential effects on the angiotensin II type 2 (AT 2 ) receptors may be important. Other important pharmacologic differences are also known to be present and may be of direct relevance. The weight of available evidence therefore supports the use of appropriate ACE inhibitor regimens, although not ARBs, in the treatment of global cardiovascular risk. Am J Hypertens 2005;18:127S-133S
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D
uring the past 26 years the primary target for drugs designed to beneficially modulate the renin-angiotensin system has been the angiotensinconverting enzyme (ACE). More recently the development of orally active selective antagonists of the angiotensin AT 1 receptor subtype has provided an alternate approach to treatment and prevention of cardiovascular disease. Although some investigators have seen the development of angiotensin receptor blockers (ARBs) as a more effective and tolerable way of reproducing the benefits of ACE inhibition, there remains important concerns regarding the distinct pharmacologic profiles and modes of action of these two classes of drugs. The ACE inhibitors are effective at reducing the morbidity and mortality of patients with overt clinical heart failure, asymptomatic left ventricular dysfunction, and uncomplicated myocardial infarction (MI). Furthermore, recent trials support wider use of this class of drug in other high-risk patients including those with hypertension. [1] [2] [3] [4] [5] This article will focus on the appropriateness of extending the use of ACE inhibitors and other modulators of the renin-angiotensin system to the routine/first-line treatment of patients with an increased "global cardiovascular risk."
The Framingham Study was the first to coin the concept of a risk factor for cardiovascular disease. These factors were subdivided into two broad categories based on the belief that the risk factor was either modifiable (eg, hypercholesterolemia, hypertension, diabetes, smoking) or nonmodifiable (eg, age, gender, ethnicity, family history). These factors have subsequently been shown to be equally predictive of noncoronary vascular events as they are of major coronary events such as fatal and nonfatal MI and sudden cardiac death. Furthermore, because each patient has a unique combination of these and other currently unknown risk factors, the concept of global cardiovascular risk has grown. Furthermore, there has been a clear shift in emphasis away from treating single risk factors/disease states (eg, hypertension or diabetes) based on the defining abnormality of those conditions (increased blood pressure [BP] and increased blood sugar) toward a more holistic approach to prevention of future cardiovascular events.
Strategy 1: ACE Inhibition
Angiotensin-converting enzyme is a cell-membrane peptidase, working as an ectoenzyme, with its catalytic site exposed at the extracellular surface of the cell. It catalyses conversion of angiotensin I (Ang I) into the active octapeptide, angiotensin lI (Ang II). The ACE has a ubiquitous tissue distribution within the vasculature, both throughout the body, and also the different cell types of the vessel wall (endothelial, vascular smooth muscle, and adventitial cells). Nevertheless, particularly high levels of the ACE are found in proximal convoluted tubules of the kidney, the coronary arteries, and the interstitial tissue of the myocardium and the aorta. In simple terms, inhibition of ACE is associated with decreased production and hence activity of Ang II (mediated by the AT 1 and AT 2 angiotensin receptor subtypes) (Fig. 1) . However, other direct and indirect effects occur, most notably a reduction in bradykinin metabolism.
HOPE, EUROPA, and PEACE
There are few more dramatic stories in modern medicine than the journey from poison to panacea that has occurred for the therapeutic class of drugs known collectively as the ACE inhibitors. Modeled on the terminal proline amino acid of a peptide derived from the venom of the Brazilian viper Bothrops jararaca, 6 captopril used a sulfhydryl active moiety to produce ACE inhibition. Because this drug was initially associated with a range of unacceptable side effects such as proteinuria, skin rashes, altered taste, other pharmaceutical companies opted to replace the sulfhydryl group with a carboxyl moiety. The potency of the interactions with the active site of the ACE of the carboxyl group was seen to relate to the degree of lipophilicity of the molecule-a property that would later prove to be an asset with regard to both 1) access to a later discovered second active site on the ACE molecule and 2) penetration of the ACE inhibitor into normal and pathologic tissues. Although all three carboxyl ACE inhibitors share a similar core structure (Fig. 2 ) in addition to a lipophilic profile and have each been evaluated in large randomized placebo controlled trials, different target dosages were selected for study: the Heart Outcomes Prevention Evaluations (HOPE) study tested ramipril (10 mg once daily); the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) perindopril (8 mg once daily); and Prevention of Events with Angiotensin-Converting Enzyme inhibition (PEACE) trandolapril (4 mg once daily).
7-9
The PEACE study investigators have just reported their observations regarding 8290 patients with overt coronary artery disease (CAD) and preserved left ventricular systolic function who were given either placebo or trandolapril at a target dose of 4 mg/d. No significant benefit from treatment was seen, in contrast to the clear findings from the previously published HOPE (9297 patients) and EUROPA (12,218 patients) trials. Although it is fully expected that meta-analysis of these three studies would also demonstrate the presence of useful clinical benefit, the possible reasons for discordance merit further careful consideration.
One notable difference in the selection criteria of PEACE was the documentation of "normal or slightly reduced left ventricular function" as this was not a feature of the other two trials. Baseline use of diuretics was higher in PEACE (13%) and HOPE (15%) than in EUROPA (9%), whereas hospitalization for heart failure during the study was higher for HOPE (0.6% per year) and PEACE (0.7% per year) than for EUROPA (0.3% per year). The supposition that covert left ventricular dysfunction in HOPE or EUROPA might explain observed clinical benefits clearly does not agree with these or other persuasive data that include a substantial subset of the HOPE study where baseline left ventricular function was documented as being normal.
The PEACE investigators wrongly state that their failure to demonstrate clinical benefits relates to an event rate that was "lower than the event rates in the ACE inhibitor groups in (the) two previous trials." Annualized all-cause mortality was similarly low in PEACE (1.6% per year) and EUROPA (1.5% per year) as compared to HOPE (2.3% per year). Furthermore, the annualized rate of occurrence 
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of the combined primary end point for PEACE was higher than for either of the other two trials-PEACE (4.6% per year), HOPE (3.2% per year), and EUROPA (2.1% per year). It is also apparent that the event rates for cardiovascular death and nonfatal MI are similarly low for PEACE (0.8% and 1.1% per year) and EUROPA (0.9% and 1.3% per year) as compared to HOPE (1.4% and 2.2% per year). These similarities in event rates are present despite significantly different baseline rates of lipid lowering and revascularization (PEACE 72% and 70%; EUROPA 58% and 57%; HOPE 28% and 44%) and must have been influenced also by the mean baseline age of patients in the three trials (EUROPA: 60 years; PEACE: 64 years; HOPE: 66 years).
The PEACE and EUROPA trials closed recruitment in the year 2000 being contemporary with regard to the published evidence base. Nevertheless, although EUROPA demonstrated a highly significant 20% relative risk reduction (95% confidence interval [CI] 9% to 29%, P Ͻ .0003) for the primary end point, PEACE observed only 4% (95% CI Ϫ6% to 12%, P ϭ .43). Importantly, EUROPA studied 4000 more patients than did the PEACE study, also opting to use a higher dose of a structurally similar ACE inhibitor (8 mg of perindopril v 4 mg of trandolapril). The stated reason for selection of 4 mg of trandolopril was the positive outcome seen for the TRAndolapril Cardiac Evaluation (TRACE) trial, which assessed survival effects in patients after MI who had an ejection fraction of less than 35%. 4 Nevertheless, the likely target for treatment in PEACE was not circulating and accessible plasma ACE but rather the large amounts of ACE expressed by macrophages located within the shoulder of atheromatous plaques. 10 Although drug penetration will have been aided by the lipophilic profile of trandolapril, as well as affinity for tissue-bound ACE, patients in the HOPE trial may have also benefited from a higher dose of a similar-sized ACE inhibitor molecule (10 mg/d of ramipril) and EU-ROPA patients from a higher dose of a smaller molecule (8 mg/d of perindopril).
11,12
Strategy 2: Angiotensin AT 1 
Receptor Blockade NOT ACE Inhibition
The angiotensin-blocking drugs are selective antagonists of the AT 1 receptor subtype leaving the AT 2 receptor subtype open to stimulation (Fig. 3) . This represents an important distinction compared to the effects of ACE inhibition. Although supporters of this class of drug speculate that the absence of an effect on bradykinin and an enhanced effect on the AT 2 receptor activation is probably beneficial, this is based largely on nonclinical studies and significant speculation. Importantly, a new drug/class of drug must demonstrate that it represents an improvement on drugs currently in use. This is judged in terms of overall safety, tolerance, affordability, and, most of all, clinical effectiveness.
Despite not being designed for this purpose the Evaluation of Losastan In The Elderly (ELITE I) Study (722 individuals with left ventricular impairment; 10 months mean follow-up) 13 was the first clinical trial to explore the survival benefits in patients who were randomized to either the ARB losartan or ACE inhibitor captopril. It appeared that patients given losartan were more likely to survive, specifically due to a reduction in sudden death. However, the difference in absolute numbers was very small (14 v 5 deaths) emphasizing that the study was not powered to be in any way conclusive regarding mortality differences. The investigators of the subsequent ELITE II Study 14 concluded that "ACE inhibitors should remain the treatment of choice in heart failure." Patients randomized to losartan had a higher rate of all-cause mortality (17.7% v 15.9%; P ϭ .16), hospitalization or all-cause mortality (47.7% v 44.9%; P ϭ .018), and also sudden death (9.0% v 7.3%; P ϭ .08), than was observed for those randomized to receive captopril. There was also a statistically significant increase in the risk of death among patients randomized to losartan who were already receiving ␤-blocker therapy (hazard ratio (HR) ϭ 1.79; P Ͻ .05). These differences in outcome occurred despite the fact that significantly more surviving patients withdrew from captopril as compared with losartan (14.7% v 9.7%; P Ͻ .01). If the two treatments were of equivalent benefit, this would have disadvantaged patients randomized to captopril compared to the ones receiving losartan.
The OPtimal Therapy In Myocardial infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) study also elected to use captopril as comparator when investigating the effects of losartan in 5477 patients with heart failure after MI (mean follow-up 2.7 years). 15 In keeping with ELITE II there was an excess risk of sudden cardiac death (HR 1.19; P ϭ .072), cardiovascular death (HR 1.17; P ϭ .032), and all-cause mortality (HR 1.13; P ϭ .069) for patients randomized to receive losartan. Of these three results, two may be considered to be mathematically (P Ͼ .05), although not clinically (consistent trend toward harm) insignificant.
Concern regarding possible harmful effects of the ARB 
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class in the treatment of heart failure patients has to some extent been diminished by the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Programme. 16 -19 However, death from all causes was not statistically different to placebo (HR 0.91; P ϭ not significant) due to differential effects on sudden cardiac death (HR 0.85; P ϭ .036) and progressive heart failure (HR 0.78; P ϭ .008) as compared to cancer deaths (HR 1.42; P ϭ .037) and myocardial infarction (HR 1.19; P ϭ .37). Although the majority of patients in these trials were prescribed concomitant ACE inhibitor therapy (see next section), comparison of candesartan and placebo in the absence of ACE inhibitor also took place in patients who were intolerant of ACE inhibitors (CHARM-Alternative). 17 This demonstrated significant reductions in all prespecified end points. However, the incidence of myocardial infarction was increased in those randomized to candesartan (HR 1.52; P ϭ .025).
Some critics have suggested that the significant benefits seen in the HOPE and EUROPA studies are entirely the result of blood pressure reduction. However, although small reductions of blood pressure may form part of the mechanism by which plaque rupture is prevented, it would be a major mistake to believe that equal benefits would be obtained by excluding nonhypertensive patients (45% of HOPE and 73% EUROPA of patients) or by opting to use alternate, untested drugs. In the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) guidelines on management of hypertension, both ACE inhibitors and ARBs are recommended for treatment of hypertensive patients with concomitant diabetes mellitus, (Table 1) .
Based on a meta-analysis of completed placebocontrolled randomized trials in patients with diabetic nephropathy, it would appear that ACE inhibitors and angiotensin receptor antagonists have qualitatively similar effects on renal outcomes (Table 2) . 20 Strippoli et al 20 concluded that "Although the survival benefits of ACE inhibitors for patients with diabetic nephropathy are known, the relative effects of ACE inhibitors and AIIRAs (angiotensin II receptor antagonists) on survival are unknown owing to the lack of adequate head to head trials." However, they also comment on the relative effects of placebo and angiotensin receptor antagonists: "In comparison [to ACEI], current trials of AIIRAs in patients with diabetic nephropathy have not shown a reduction in all cause mortality . . ." and also that "For all-cause mortality, the absence of benefit shown by AIIRAs is unlikely to be due to chance alone . . ." Consequently, although there is evidence that ACE inhibitors extend the lives of patients with diabetic nephropathy, there is a notable absence of similar data for the angiotensin receptor antagonist class.
Strategy 3: Angiotensin AT 1 Receptor Blockade AND ACE Inhibition
Modulation of the renin-angiotensin system using ACE inhibitors was first attempted in patients with extreme forms of renal hypertension and then in patients with very severe congestive cardiac failure. In both instances, the presence of high plasma renin levels suggests the potential value of such an approach. The concomitant use of loop diuretics produces additional activation of this system, to a degree that can only be partially inhibited by recommended doses of ACE inhibitor therapy. In the presence of detectable levels of Ang II, the concomitant use of an ARB might produce additional benefits (Fig. 4) 16, 18, [21] [22] [23] each failed to demonstrate a superior effect with regard to reduction of all-cause mortality despite attenuating progression of overt clinical heart failure.
Conclusion
Likely mechanisms by which the lipophilic ACE inhibitors ramipril and perindopril prevent plaque rupture, is by 1) inhibiting both active sites of the angiotensin-converting enzyme (C and N terminal); 2) penetrating the shoulder of atheromatous plaques to reach and inhibit the large amounts of ACE expressed by inflammatory macrophages; and 3) prevention of tissue Ang II production and thereby reducing stimulation of the angiotensin II AT 2 receptors expressed by macrophages. This has been shown to prevent AT 2 receptor-mediated release of various enzymes able to breakdown connective tissue proteins. Consequently, substitution of an Ang II AT 1 receptor anatagonist would not be expected to produce equivalent effects.
In the case of losartan another mechanism may explain a failure to reduce the occurrence of MI. As a prodrug dependent on first-pass metabolism in the liver, losartan is converted into two different metabolites. The first of these (EXP3174) is a potent antagonist of the AT 1 receptor and accounts for 14% of the parent molecule. A second metabolite (EXP3179) has a structure similar to indomethacin and accounts for 86% of the parent molecule. Among other actions, this second metabolite inhibits the COX-2 enzyme, 24, 25 an effect that may be undesirable in patients with increased global cardiovascular risk. This mechanism may also helps to explain why MI was not reduced in the patients in the Losartan Intervention For End point reduction in hypertension (LIFE) study 26 who had hypertension and also left ventricular hypertrophy-an observation that was at odds with observed reductions in stroke. This would suggest that losartan is having more than one effect-as suggested by the known pharmacokinetics of the molecules. 24, 25 Although it remains unclear to what extent other ARBs (Fig. 5) and their metabolites may also act as COX-2 inhibitors, an excess rate of MI is consistently apparent.
27, 28 The weight of available evidence therefore supports the use of appropriate ACE inhibitors, not ARBs, in the treatment of global cardiovascular risk.
